HPgV-1 reduced IL-2 and PHA stimulated latent HIV reactivation in vitro, suggesting that HPgV-1 may hinder activation-induced therapeutic “cure” strategies for HIV, especially since up to 41% of PLWH HPgV-1 coinfection (84, 114, 194). The gene discussed is IL2; the disease is coinfection.